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Human mast cells have been shown to release histamine in response to the neuropeptide a-melanocyte-
stimulating hormone (a-MSH), but it is unknown whether these cells express proopiomelanocortin (POMC) or
POMC-derived peptides. We therefore examined highly purified human skin mast cells and a leukemic mast cell
line-1 (HMC-1) for their ability to express POMC and members of the prohormone convertase (PC) family
known to process POMC. Furthermore, we investigated whether these cells store and secrete a-MSH. Reverse
transcriptase-PCR (RT-PCR) analysis revealed that both skin mast cells and HMC-1 cells express POMC mRNA
and protein. Expression of the POMC gene at the RNA level in HMC-1 cells could be confirmed by Northern
blotting. Transcripts for both PC1 and furin convertase were detectable in skin-derived mast cells and HMC-1
cells, as shown by RT-PCR. In contrast, PC2 transcripts were detected only in skin mast cells, whereas transcripts
for paired basic amino acid converting enzyme 4 (PACE4) were present only in HMC-1 cells. Radio-
immunoassays performed on cell lysates and cell culture supernatants from human skin-derived mast cells
disclosed immunoreactive amounts of a-MSH in both fractions. Stimulation with an anti-IgE antibody
significantly reduced intracellular a-MSH and increased extracellular levels, indicating IgE-mediated secretion of
this neuropeptide. Our findings show that human mast cells are active players in the cutaneous POMC system.
Mast cell-derived a-MSH may contribute to cutaneous hyperpigmentation as seen in patients with urticaria
pigmentosa. Moreover, IgE-dependent release of a-MSH suggests an immunomodulatory role of this
neurohormone during inflammatory and allergic reactions of the skin.
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INTRODUCTION
Mast cells are connective tissue-resident cells that are best
known for their histamine- and leukotriene-mediated primary
effector function during anaphylactic reactions. In recent
years, there is however increasing evidence that these cells
participate in various other immunological and inflammatory
reactions, particularly through the generation and release of
a broad spectrum of chemokines and peptide growth factors
(reviewed by Henz et al., 2001). Since many decades, mast
cells have also been considered as regulators of neuro-
hormonal reactions, but the molecular mechanisms under-
lying these phenomena are poorly clarified (see Metcalfe
et al., 1997 for a review). An important regulatory module of
the immune-neurohormonal axis is the proopiomelanocortin
(POMC) system. POMC-derived peptides such as adreno-
corticotropin (ACTH), a-melanocyte-stimulating hormone
(a-MSH), and b-endorphin are released in response to stress-
related stimuli not only from the anterior pituitary but also
from various cells within peripheral tissue like the skin. These
molecules are of particular interest in cutaneous biology and
pathology as they are not only involved in thermoregulation,
melanin synthesis, and hair growth, but also in diverse
immunological and inflammatory reactions in response to UV
radiation and inflammatory stimuli (reviewed by Slominski
et al., 2000).
A possible role for POMC-derived peptides in mast cell-
dependent allergic reactions has recently been substantiated
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as cutaneous mast cells respond to a-MSH with the selec-
tive release of histamine (Gru¨tzkau et al., 2000). Interestingly,
more than one decade ago, immunohistochemical studies
on skin sections from patients with urticaria pigmentosa
demonstrated immunoreactivity for ACTH in cutaneous
mast cells in situ (Akiyama et al., 1991). Direct evidence
for the expression of the POMC gene and/or precursor
proteases that process POMC into POMC-derived peptides,
that is, prohormone convertase (PC)1, PC2, furin convertase
(FC), and paired basic amino acid converting enzyme 4
(PACE4) (reviewed by Seidah et al., 1999), is however lacking
in mast cells.
In this study, we have therefore investigated whether
human cutaneous mast cells as well as a human leukemic
mast cell line (HMC-1) express POMC and precursor pro-
teases. Furthermore, we have studied the release of
a-MSH by FceRI-dependent pathways. Our data provide
first evidence that human mast cells express the POMC gene
and possess the enzymatic machinery to process this pre-
cursor hormone. We also demonstrate that human mast cells
generate and secrete immunoreactive amounts of a-MSH, a
process augmented by stimulation of the cells with anti-IgE
antibodies. These findings provide novel clues to our under-
standing of pigmentary changes in patients with cutaneous
mastocytosis and furthermore suggest mast cell-derived
a-MSH as a novel modulator of inflammatory/allergic skin
reactions.
RESULTS
Human skin mast cells and HMC-1 cells express POMC mRNA
and protein
Reverse transcriptase-PCR (RT-PCR) analysis of RNA derived
from freshly isolated, unstimulated human mast cells as well
as from HMC-1 cells (data not shown) revealed positive
signals for POMC (Figure 1a, lane 1). The amplification
product was of the expected size of 260 bp, corresponding to
exon 3 of the POMC gene (Slominski et al., 1995). The
POMC-related amplification products of human skin mast
cells and HMC-1 cells comigrated exactly with an amplicon
generated by RT-PCR from RNA derived from human
keratinocytes serving as positive control (data not shown).
To substantiate the expression of POMC in skin-derived
human mast cells and HMC-1 cells, Western immunoblotting
was performed using an antibody directed against ACTH
18–33 that cross-reacts with POMC (Schiller et al., 2001;
Bo¨hm et al., 2005). In normal human melanocytes used as a
positive control, two immunoreactive bands at 33 and
31 kDa were detected, possibly representing differentially
glycosylated POMC isoforms (Figure 1b). Skin-derived hu-
man mast cells expressed only the 33 kDa form, whereas
HMC-1 cells expressed only the 31 kDa form. In contrast, cell
extracts from the neuroblastoma cell line SK-N-MC lacking
POMC expression (Verbeeck et al., 1992) did not show any
POMC-related immunoreactive band. Stripping of the origi-
nal blot and reprobing with an antibody against the
ubiquitously expressed extracellular kinase-2 indicate that
the absence of a POMC-related band in SK-N-MC cells was
not owing to a lack of protein in the sample (Figure 1b).
Detection of transcripts for precursor proteases in human
skin-derived mast cells and HMC-1 cells
To further check whether human skin mast cells and HMC-1
cells possess the enzymatic equipment to cleave POMC into
POMC-derived peptides, we performed RT-PCR analysis with
primers against all members of the PC family of serine
proteases that are capable of processing POMC (Seidah et al.,
1999). In human skin, mast cell expression of both PC1 and
PC2 was detectable (Figure 1a, lanes 2 and 3), whereas in
HMC-1 cells, only PC1 could be detected (data not shown).
The PC1- and PC2-related amplification products in skin mast
cells were of the expected size of 674 and 299 bp (Schiller
et al., 2001; Bo¨hm et al., 2005). FC, another member of the
PC family, was also detectable in both human skin mast cells
and HMC-1, cells as shown by RT-PCR and amplification of
a specific product of 111 bp (Figure 1c). On the other hand,
transcripts for PACE4 were detected only in HMC-1 cells but
not in human skin mast cells (Figure 1d). In both of the latter
RT-PCR analyses, RNA from human epidermal keratinocytes
served as positive control (Pearton et al., 2001), generating
expected bands with a size of 111 bp (for FC) and of 456 bp
(for PACE4), respectively. Negative controls with substitution
of the template with H2O were consistently negative (data not
shown).
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Figure 1. Detection of POMC and precursor proteases in purified human
skin MC and HMC-1 cells. (a) Total RNA was extracted from the above
cells, reverse-transcribed, and amplified with specific primers against
POMC (lane 1, 260 bp), PC2 (lane 2, 299 bp), and PC1 (lane 3, 674 bp)
followed by agarose gel electrophoresis. FC and PACE were amplified
with specific primers yielding amplicons of 111 and 456 bp. (c, d) cDNA from
normal human keratinocytes (NHK) served as positive control for FC and
PACE4. For detection of POMC protein, identical amounts of protein
(50mg/lane) were subjected to SDS-PAGE and Western immunoblotting
using an antibody against ACTH that cross-reacts with POMC. (b, upper
panel) As a positive control, lysates from normal human melanocytes
(NHM) and as a negative control lysates from SK-N-MC cells were used.
(b, lower panel) For control of identical protein loading, the membrane
was reprobed with an antibody that detects the ubiquitously expressed
extracellular kinase 2.
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Production and secretion of a-MSH by human dermal mast cells
and HMC-1 cells
In order to assess the biological relevance of POMC, PC1,
and PC2 expression in human mast cells, we investigated the
production and secretion of a-MSH in human skin-derived
mast cells under basal conditions and after treatment with an
anti-IgE antibody. Cross-linking of mast cells bound IgE with
antibodies against IgE or treatment with anti-FceRI antibodies
are well-established experimental procedures mimicking the
IgE-dependent effector pathway in vivo. Figure 2a shows the
detected amounts of a-MSH as measured by radioimmuno-
assay in skin mast cells under basal conditions (i.e. in
cells kept in culture medium for 24 hours) and in cells treated
with an anti-IgE antibody over the same period of time.
Intracellular levels of a-MSH (as represented by cell lysates)
were higher (mean: 84.2714.2 pmol/106 cells) than those
amounts found in cell culture supernatants (mean: 17.757
1.8 pmol/106 cells). In cells treated with the anti-IgE antibody
for 24 hours, intracellular a-MSH levels slightly declined as
compared to non-stimulated cells. Most interestingly, com-
pared to cells kept in culture medium only, a robust increase
(Po0.05) in the amount of extracellular a-MSH (40.57
10.1 pmol/106 cells) was noted, suggesting together with the
aforementioned observation release of a-MSH from intracel-
lular stores. In HMC-1 cells, immunoreactive amounts of
a-MSH were also detectable in intracellular and extracellular
fractions (Figure 2a). Treatment of HMC-1 cells with phospho-
ramidon, a pharmacological inhibitor of neutral endopeptidase
(NEP) 24.11, resulted in a marked decrease of a-MSH as
compared to controls (data not shown).
As the kinetics of mediator release from mast cells differs
widely depending on the type of mediator and stimulus
studied, a more detailed study of a-MSH release was con-
ducted with human skin-derived mast cells (Figure 2b). After
1 hour of treatment with the anti-IgE antibody, a-MSH levels
in the cell culture supernatants were about the same between
non-stimulated and stimulated cells. Anti-IgE treatment
resulted in a robust increase of a-MSH at later time points,
with peak values at 3–4 hours. Values for non-stimulated
cells dropped, on the other hand, slightly by 2 hours of
incubation, and remained more or less at the 1-hour value
over the entire time of incubation.
DISCUSSION
The present data provide first evidence for an active
contribution of mast cells to peripheral tissue POMC-derived
peptide levels by demonstrating expression of the POMC
gene and generation of immunoreactive amounts of a-MSH.
As an essential prerequisite for POMC peptide generation,
both human skin-derived mast cells and HMC-1 cells were
found to express members of the PC family of precursor
proteases that are capable of processing POMC into a-MSH
(Seidah et al., 1999). Indeed, the skin mast cell used for our
investigative studies derived from foreskin a specialized
‘‘sexual’’ tissue, which is densely innervated and contains
many peptidergic nerves (Vaalasti et al., 1988). However,
it remains speculative whether mast cells from foreskin are
different from mast derived from skin of other body sites with
regard to expression of POMC, PCs, or a-MSH secretion. The
foreskin-derived mast cells used in our studies expressed PC1
and PC2 similar to human epidermal melanocytes (Peters
et al., 2000) and dermal fibroblasts (Schiller et al., 2001) and
several cell types of murine skin (Mazurkiewicz et al., 2000).
However, in this study, we were unable to detect PC2
transcripts in HMC-1 cells, although this transformed cell line
expressed FC. It has been reported that cellular transforma-
tion can be associated with loss of neuroendocrine differen-
tiation markers such as PC1 and PC2 (Scopsi et al., 1995).
In light of the detected a-MSH in HMC-1 cells, it is possible
that POMC processing is mediated via FC and PC1, or by an
alternative mechanism. Accordingly, we could demonstrate
that the amounts of a-MSH released by HMC-1 cells decline
in cells treated with the NEP 24.11 inhibitor phospho-
ramidon. Previously, it had been shown that NEP 24.11 can
convert ACTH into a-MSH (Smith et al., 1992). Therefore,
it will be interesting to investigate the expression of NEP
24.11 and its putative ACTH-converting activity in skin-
derived mast cells and HMC-1 cells in more detail.
In recent years, it has become apparent that the rapid
death of tissue mast cells during in vitro culture can be
prevented by the addition of stem cell factor (SCF) and IL-4.
This has been shown for intestinal mast cells (Bischoff et al.,
1999) and has been confirmed by us regarding skin mast cells
(Babina et al., 2004). These molecules act synergistically in
that SCF alone has only minor effects on mature mast cells,
but in the presence of IL-4, there was a strong increase of
proliferation, an enhancement of IgE-dependent mediator
release, and furthermore a switch to a Th-2 type cytokine
pattern (Bischoff et al., 1999; Lorentz et al., 2000). SCF is
also a well-known secretagogue for human skin mast cells
(Frenz et al., 1997; Gibbs et al., 2001). We can therefore not
exclude that priming with SCF and IL-4 might have induced
the production and baseline secretion of a-MSH, or at least
caused an enhancement of this process. A major direct secre-
tory effect of SCF is, however, unlikely as this requires an
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Figure 2. Detection of a-MSH in purified human skin mast cells. For
measuring intracellular and secreted fractions pf, a-MSH cells were kept in
culture medium alone (columns 1 and 2) or stimulated with anti-IgE (columns
3 and 4) for 24 hours. Amounts of a-MSH are expressed in absolute values
(pmol). (a) Data show means7SD of eight separate experiments. Columns 1
and 3: cell lysates; columns 2 and 4: cell supernatants. For analysis of the
time-dependent release of a-MSH in response to anti-IgE, cells were kept
in medium (basal) or in medium plus anti-IgE (anti-IgE). Amounts of a-MSH
are expressed in absolute values (pmol). (b) Data show means7SD of three
separate experiments. *Po0.05, compared with non-stimulated mast cells.
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extended time period (Gibbs et al., 2001). Furthermore, the
fact that POMC, PC1, PC2, and FC are expressed in freshly
isolated mast cells make a basic, constitutional ability of mast
cells to produce this molecule more likely. Moreover, the
detection of POMC and immunoreactive amounts of a-MSH
in HMC-1 cells support a constitutive production of a-MSH
by mast cells. Interestingly, HMC-1 cells are able to grow
independently of externally added SCF owing to an activating
SCF mutation (Furitsu et al., 1993) so that an SCF effect is
endogenously operative. This may also explain why HMC-1
cells express a full-length transcript of the POMC gene,
whereas no or only a truncated form of the POMC gene has
been found in other monocytic and T-lymphoblastic leuke-
mic cell lines (Murao et al., 1998). However, as HMC-1 cells
respond only poorly or not at all to IgE receptor cross-linking
(Butterfield et al., 1988; Weber et al., 1996), we could not
examine whether the cells are also able to secrete a-MSH.
The fact that mast cells generate POMC-derived peptides
such as a-MSH has several novel implications for the
cutaneous neurohormonal network. Accordingly, a-MSH
released by mast cells may be involved in the pathogenesis
of cutaneous hyperpigmentation in patients with urticaria
pigmentosa, a skin disease well characterized by interstitial
accumulation of mast cells that may fill-out the whole
papillary dermis. Typically, the dermatopathologic picture of
lesional skin in these patients also includes increased
epidermal melanization, a finding possibly related to
a-MSH released by the increased numbers of dermal mast
cells. It should, however, be noted that mast cell secrete a
plethora of growth factors, cytokines, and mediators, many of
which can stimulate melanogenesis (reviewed by Slominski
et al., 2004). Thus, future studies are needed to clarify
whether a-MSH derived from mast cells is biologically active
and to what extent it contributes to the overall pigmentary
activity of mast cell mediators. Another novel aspect of
neurohormonal regulation by mast cells as shown by our
study is the IgE-dependent release of a-MSH. It is known that
activation of mast cells by anti-IgE antibodies also leads to the
release of the proinflammatory cytokines tumor necrosis
factor-a and IL-8 within 2–4 hours (Gibbs et al., 2001). Our
data on the IgE-mediated release of a-MSH extend these
findings and, moreover, show that the time course of a-MSH
secretion by skin mast cells follows a similar pattern like that
of tumor necrosis factor-a and IL-8. It is difficult to speculate
on the immunoregulatory function of a-MSH released by
mast cells. We have previously reported that human mast
cells express receptors for a-MSH and that a-MSH treatment
of these cells induces histamine release (Gru¨tzkau et al.,
2000). These findings would actually suggest an autocrine
proallergic or proinflammatory role of a-MSH in mast cells.
In light of the majority of reported modulatory actions of
a-MSH (Lipton and Catania, 1997; Luger et al., 1999), this
neuropeptide may, however, rather act as a paracrine regu-
lator limiting the extent of inflammatory, immune, or allergic
reactions.
Besides the IgE-mediated activation pathway, mast cells
can be stimulated to release histamine, leukotrienes, cyto-
kines, and growth factors by polybasic molecules such as
mastaropan, and Compound 40/80, by peptide-like sub-
stances such as substance P, calcitonin gene-related peptides,
somatostatin, neurotensin, and vasoactive intestinal peptide
or by the complement fragments C3a and C5a (reviewed by
Metcalfe et al., 1997; Henz et al., 2001). In the past, some of
these molecules, like histamine and tumor necrosis factor-a,
have been implicated in the increase of a-MSH production in
rat tissue and in monocytes/macrophages, respectively (Kjaer
et al., 1995; Knigge et al., 1995; Taherzadeh et al., 1999).
A stimulatory effect of the above factors on POMC expres-
sion, POMC processing, or release of a-MSH by mast cells
is thus well possible in view of the fact that they belong to
the monocyte/macrophage lineage as well (Metcalfe et al.,
1997). In addition, UV light has been reported as another
potent means by which a-MSH and ACTH are upregulated
in several cutaneous cell types (Chakraborty et al., 1996;
Scholzen et al., 2000). Recent findings demonstrating the
modulatory role of UV radiation also in cutaneous mast
cells, in view of these findings, and, with a clear reduction
of mediator release from mast cells on their in vitro exposure
to UV light (Horio, 2000; Guhl et al., 2005), would underline
a potential role of a-MSH in this process.
Taken together, the data as presented in this report are
a first demonstration of the ability of cutaneous mast cells
to synthesize and release the POMC peptide a-MSH. a-MSH
may be one of the mediators responsible for cutaneous
hyperpigmentation in skin diseases with increased numbers
of dermal mast cells. Furthermore, the identification of an IgE-
mediated secretory stimulus for this molecule, the kinetics of
its release, and the findings reported on other secretory
stimuli in other cell types of the skin suggest that mast
cell-derived a-MSH may play an important role during the
so-called delayed allergic reactions. Our findings further
emphasize the existence of an intricate interactive network
of mediator interplay between immune regulators and
neurohormones in the skin. Clarification of the role of
mast cell-derived a-MSH may not only shed light on the
ever-increasing spectrum of biological activities of this mole-
cule but may also help to better understand the pathogenesis
of inflammatory, immune, and allergic diseases of the skin.
MATERIALS AND METHODS
Mast cells
Tissue mast cells were isolated from human foreskins. All use of human
skin was conducted according to the Declaration of Helsinki Principles
and was approved by Institutional Review Boards of Universita¨tsme-
dizin Berlin Charite. Cells were enriched by a sequence of enzymatic
and mechanical tissue dispersions, followed by affinity purification
with magnetic beads and a monoclonal antibody mAB YB5.B8 (kindly
provided by L. Ashman, Adelaide, SW Australia) directed against the
Kit receptor (CD 117). Final purity of mast cells was always490%, as
measured by flow cytometry using the c-kit receptor and the a-chain of
the high-affinity IgE receptor as markers. Viability of mast cells was
always 495%, as determined by Trypan blue staining. For further
details, see Gru¨tzkau et al. (2000) and Artuc et al. (2002). The human
leukemic mast cell line (HMC-1) was kindly provided by J.H.
Butterfield, Rochester, MN). Cells were routinely grown as described
before (Butterfield et al., 1988; Artuc et al., 2002).
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RT-PCR
For RT-PCR, total RNA was isolated from purified human mast cells
using the RNAesy system (Qiagen, Hilden, Germany), treated with
RNAse-free DNAse to digest genomic DNA and, after ethanol
precipitation, reverse-transcribed, as detailed recently (Artuc et al.,
2002). Successful cDNA synthesis was checked by PCR using
glyceraldehyde-3-phosphate dehydrogenase-specific primers (sense:
50-GATGACATCAAGAAGGTGGTG-30 and antisense: 50-GCTGTAG
CCAAATTCGTTGTC-30; product size: 190 bp) and 20 cycles of PCR
(951C for 45 seconds, 581C for 45 seconds, and 721C for 45 seconds),
followed by a 10-minute extension step at 721C. Nucleotide
sequences for PC-1 and PC-2 primers and the corresponding
amplification program were previously described by Schiller et al.
(2001). PC-1 was amplified with the sense primer 50-AGCAAACCCA
ATCTCACCTG-30 and the antisense primer 50-TCTCCACCCCTCCT
CTGTCAT-30, yielding a 674 bp cDNA product by one cycle at 941C
for 10 minutes, 531C for 45 seconds, 721C for 1 minute, followed
by 39 cycles at 941C for 45 seconds, 531C for 45 seconds, 721C
for 1 minute, and a final cycle at 941C for 45 seconds, 531C
for 45 seconds, 721C for 10 minutes; PC-2 was amplified with the
sense primer 50-AACGCAACCAGAAGAGGAGA-30 and the anti-
sense primer 50-ATGGCCAACTTGGACTGGTA-30, yielding a 299 bp
cDNA product by one cycle at 941C for 10 minutes, 531C for
45 seconds, 721C for 1 minute, followed by 39 cycles at 941C for
45 seconds, 531C for 45 seconds, 721C for 1 minute, and a final cycle
at 941C for 45 seconds, 531C for 45 seconds, 721C for 10 minutes.
POMC was amplified by primer pairs established by Slominski
et al. (1995) and a modified protocol, with one cycle at 941C for
10 minutes, 681C for 45 seconds, 721C for 1 minute, followed by
39 cycles at 941C for 45 seconds, 681C for 45 seconds, 721C
for 1 minute, and a final cycle at 941C for 45 seconds, 681C for
45 seconds, 721C for 10 minutes. PACE4 was detected with primer
pairs established by Cheng et al. (1997) generating an amplification
product of 456 bp. The nucleotide sequence of the sense primer was
50-CTATGGATTTGGTTTGGTGGAC-30 and that of the antisense
primer 50-AGGCTCCATTCTTTCAACTTCC-30. The thermocycler
program consisted of one cycle at 941C for 5 minutes, 571C for
45 seconds, 721C for 1 minute, followed by 35 cycles at 941C for
45 seconds, 571C for 45 seconds, 721C for 1 minute, and a final
cycle at 941C for 45 seconds, 571C for 45 seconds, 721C for
10 minutes. For the detection of FC, recently established primer sets
and conditions were used (Bo¨hm et al., 2005). Sense primer
sequence was 50-TGC TGGTCTTCGTCACTGTC-30, and antisense
primer sequence was 50-TTGTAGGAGATGAGGCCACGG-30 yield-
ing a 111 bp product. The amplification protocol was one cycle at
941C for 5 minutes, 601C for 1 minute, 721C for 2 minutes; 35 cycles
at 941C for 45 seconds, 601C for 2 minutes, 721C for 1 minute,
followed by a final cycle at 941C for 45 seconds, 601C for 1 minute,
and 721C for 10 minutes. PCR products were visualized after sepa-
ration on 1.5–2% tris-acetate-ethylenediamine tetraacetic acid
(TAE)–agarose gels by staining with ethidium bromide and detected
by the gel analysis software Grab IT.
Western immunoblotting
The cells were washed twice in phosphate-buffered saline, lysed in
ice-cold lysis puffer (1 mM HEPES, 0.5% NP40, 0.5 mM MgCl2, 0.1%
SDS, 1mg aprotonin/ml, 1 mg/ml leupeptin, 1 mM phenylmethyl-
sulfonyl fluoride), and then centrifuged at 41C for 10 minutes at
10,000 g. Protein concentration was determined with the Coomassie
Plus protein assay kit. Equal protein amounts (50 mg/lane) were
separated by denaturing SDS-PAGE using 4–12% gradient gels
(NuPAGE; Invitrogen, Carlsbad, CA). After Western blotting onto
polyvinylidene difluoride membranes and blocking with 10%
bovine serum albumin, membranes were incubated with an anti-
ACTH antibody (Sigma, St Louis, MI) directed against the amino
acids 18–39 of ACTH (1:1,000). As reported previously, this antibody
cross-reacts with POMC (Schiller et al., 2001; Bo¨hm et al., 2005),
which also contains the amino acids 18–39 of ACTH. After washing,
membranes were incubated for 20 minutes with a horseradish-
peroxidase-conjugated secondary antibody (1:10,000; Amersham
Life Science, Freiburg, Germany). Antigen–antibody complexes
were visualized by enhanced chemiluminescence (Amersham).
Membranes were stripped as detailed before (Bo¨hm et al., 1995),
re-blocked, and incubated with an anti-extracellular signal-regulated
kinase-1–4 antibody (1:5,000; BD Biosciences, Erembodegem,
Belgium) to confirm identical loading of the lanes.
a-MSH radioimmunoassay
For quantitative determination of a-MSH, cell supernatants or cell
lysates were harvested using the following protocol: purified mast
cells were suspended in RPMI 1640 medium, supplemented with
SCF, 50 ng (R&D Systems, Wiesbaden, Germany), and IL-4, 10 ng
(R&D Systems, Wiesbaden, Germany) at a density of 106 cells/ml,
and were kept as such or stimulated with an anti-IgE antibody
(1/1000 dilution; Sigma) for up to 24 hours. Thereafter, supernatants
were collected after centrifugation for 5 minutes at 5,000 r.p.m.
and immediately stored at 801C. Cells pellets were washed with
phosphate-buffered saline, lysed with 1% Triton X-100, and stored
as described above. Total protein content of cell lysates was
determined using the Bio-Rad micro protein assay system (Bio-Rad
Laboratories GmbH, Mu¨nchen, Germany). Amounts of a-MSH in
cell lysates and in cell culture supernatants were analyzed using
a commercially available radioimmunoassay (EuroDiagnostica,
Malmo¨, Sweden). The antiserum used in the a-MSH radioimmuno-
assay was directed against the C-terminal part of a-MSH recognizing
a-MSH and Des-acetyl a-MSH, with no cross-reactivity against
ACTH, b-MSH, or g-MSH. To test for the involvement of NEP 24.11
in a-MSH synthesis, HMC-1 cells were incubated overnight with
the endopeptidase inhibitor phosphoramidon (104–107 M). The
amount of a-MSH was subsequently determined in the medium
by radioimmunoassay.
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